Long-term CD4+lymphocyte response following HAART initiation in a US Military prospective cohort

被引:33
作者
Lifson, Alan R. [1 ,8 ]
Krantz, Elizabeth M. [2 ,8 ]
Eberly, Lynn E. [2 ,8 ]
Dolan, Matthew J. [3 ]
Marconi, Vincent C. [4 ]
Weintrob, Amy C. [5 ,8 ]
Crum-Cianflone, Nancy F. [6 ,8 ]
Ganesan, Anuradha [7 ,8 ]
Grambsch, Patricia L. [2 ,8 ]
Agan, Brian K. [8 ]
机构
[1] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Biostat, Minneapolis, MN USA
[3] Wilford Hall USAF Med Ctr, Def Inst Mil Operat, San Antonio, TX 78236 USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[6] USN, San Diego Med Ctr, San Diego, CA 92152 USA
[7] Natl Naval Med Ctr, Bethesda, MD USA
[8] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA
基金
美国国家卫生研究院;
关键词
Human Immunodeficiency Virus; Viral Load; Human Immunodeficiency Virus Infection; Viral Suppression; Human Immunodeficiency Virus Test;
D O I
10.1186/1742-6405-8-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Among HIV-infected persons initiating highly active antiretroviral therapy (HAART), early CD4+ lymphocyte count increases are well described. However, whether CD4+ levels continue to increase or plateau after 4-6 years is controversial. Methods: To address this question and identify other determinants of CD4+ response, we analyzed data for 1,846 persons from a prospective HIV military cohort study who initiated HAART, who had post-HAART CD4+ measurements, and for whom HIV seroconversion (SC) date was estimated. Results: CD4+ count at HAART initiation was <= 200 cells/mm(3) for 23%, 201-349 for 31%, 350-499 for 27%, and >= 500 for 19%. The first 6 months post-HAART, the greatest CD4+ increases (93-151 cells) occurred, with lesser increases (22-36 cells/year) through the first four years. Although CD4+ changes for the entire cohort were relatively flat thereafter, HIV viral load (VL) suppressors showed continued increases of 12-16 cells/year. In multivariate analysis adjusting for baseline CD4+ and post-HAART time interval, CD4+ responses were poorer in those with: longer time from HIV SC to HAART start, lower pre-HAART CD4+ nadir, higher pre-HAART VL, and clinical AIDS before HAART (P < 0.05). Conclusions: Small but positive long-term increases in CD4+ count in virally suppressed patients were observed. CD4+ response to HAART is influenced by multiple factors including duration of preceding HIV infection, and optimized if treatment is started with virally suppressive therapy as early as possible.
引用
收藏
页数:11
相关论文
共 37 条
[1]   Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada [J].
Althoff, Keri N. ;
Gange, Stephen J. ;
Klein, Marina B. ;
Brooks, John T. ;
Hogg, Robert S. ;
Bosch, Ronald J. ;
Horberg, Michael A. ;
Saag, Michael S. ;
Kitahata, Mari M. ;
Justice, Amy C. ;
Gebo, Kelly A. ;
Eron, Joseph J. ;
Rourke, Sean B. ;
Gill, M. John ;
Rodriguez, Benigno ;
Sterling, Timothy R. ;
Calzavara, Liviana M. ;
Deeks, Steven G. ;
Martin, Jeffrey N. ;
Rachlis, Anita R. ;
Napravnik, Sonia ;
Jacobson, Lisa P. ;
Kirk, Gregory D. ;
Collier, Ann C. ;
Benson, Constance A. ;
Silverberg, Michael J. ;
Kushel, Margot ;
Goedert, James J. ;
McKaig, Rosemary G. ;
Van Rompaey, Stephen E. ;
Zhang, Jinbing ;
Moore, Richard D. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (11) :1512-1520
[2]  
[Anonymous], 1992, Morbidity and mortality weekly report, V41, P1
[3]  
[Anonymous], 2009, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, P1
[4]  
[Anonymous], 2009, Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents
[5]   Poor initial CD4+recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases [J].
Baker, Jason V. ;
Peng, Grace ;
Rapkin, Joshua ;
Krason, David ;
Reilly, Cavan ;
Cavert, Winston P. ;
Abrams, Donald I. ;
MacArthur, Rodger D. ;
Henry, Keith ;
Neaton, James D. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (05) :541-546
[6]   Immunological recovery and antiretroviral therapy in HIV-1 infection [J].
Battegay, M ;
Nuesch, R ;
Hirschel, B ;
Kaufmann, GR .
LANCET INFECTIOUS DISEASES, 2006, 6 (05) :280-287
[7]   Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion [J].
Brodine, SK ;
Shaffer, RA ;
Starkey, MJ ;
Tasker, SA ;
Gilcrest, JL ;
Louder, MK ;
Barile, A ;
VanCott, TC ;
Vahey, MT ;
McCutchan, FE ;
Birx, DL ;
Richman, DD ;
Mascola, JR .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :502-+
[8]   Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues [J].
Bucy, RP ;
Hockett, RD ;
Derdeyn, CA ;
Saag, MS ;
Squires, K ;
Sillers, M ;
Mitsuyasu, RT ;
Kilby, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (10) :1391-1398
[9]   Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years [J].
Chun, Helen M. ;
Fieberg, Ann M. ;
Hullsiek, Katherine Huppler ;
Lifson, Alan R. ;
Crum-Cianflone, Nancy F. ;
Weintrob, Amy C. ;
Ganesan, Anuradha ;
Barthel, Robert V. ;
Bradley, William P. ;
Agan, Brian K. ;
Landrum, Michael L. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (03) :426-436
[10]   Accounting for leadtime in cohort studies:: evaluating when to initiate HIV therapies [J].
Cole, SR ;
Li, R ;
Anastos, K ;
Deteis, R ;
Young, M ;
Chmiel, JS ;
Muñoz, A .
STATISTICS IN MEDICINE, 2004, 23 (21) :3351-3363